Abstract
Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
Original language | English |
---|---|
Pages (from-to) | 242-258 |
Number of pages | 17 |
Journal | Clinica Chimica Acta |
Volume | 425 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- acting beta(2)-adrenoreceptor agonists
- chromatography-mass spectrometry
- molecularly imprinted polymers
- obstructive pulmonary-disease
- beta-adrenergic agonists
- performance liquid-chromatography
- 2-dimensional gas-chromatography
- developed bronchodilati